Boxer Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Boxer Capital’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-50,000	Closed	-$1.77M	–	30
2018 Q1	$1.77M	Buy	+50,000	New	+$2M	0.19%	29

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital's RIGL Position: Q4 2018 in Review

Boxer Capital sold out of Rigel Pharmaceuticals (RIGL) in Q4 2018, closing a stake of 232,190 shares — an estimated $7.45M sold.

Boxer Capital first reported a position in RIGL in Q2 2016 and held it in 6 quarters. The position peaked at $18.2M in Q1 2018. 133 funds tracked by Wall St. Rank hold RIGL as of Q4 2018.

Boxer Capital reported no remaining Rigel Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Boxer Capital sold 232,190 Rigel Pharmaceuticals shares in Q4 2018, an estimated $7.45M.
Boxer Capital first reported a position in Rigel Pharmaceuticals in Q2 2016 and held it in 6 quarters.
Boxer Capital's Rigel Pharmaceuticals position peaked at $18.2M in Q1 2018.
133 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2018.

Based on Boxer Capital's 13F filing for Q4 2018, filed 14 Feb 2019.